MGMT and alpha thalassemia spectrum: Throughout the years, several molecular alterations have been proposed as biomarkers of prognosis or response to therapy, such as O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation, EGFR amplification, Phosphatase and Tensin Homologue (PTEN) deletion, and alpha thalassemia/mental retardation syndrome X-linked (ATRX) and TERT mutations [15,16,22,24].